Literature DB >> 22321046

Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.

Yoshie Yoshikawa1, Ayuko Sato, Tohru Tsujimura, Mitsuru Emi, Tomonori Morinaga, Kazuya Fukuoka, Shusai Yamada, Aki Murakami, Nobuyuki Kondo, Seiji Matsumoto, Yoshitomo Okumura, Fumihiro Tanaka, Seiki Hasegawa, Takashi Nakano, Tomoko Hashimoto-Tamaoki.   

Abstract

In the present study, we analyzed genomic alterations of BRCA1-associated protein 1 (BAP1) in 23 malignant mesotheliomas (MMs), 16 epithelioid and seven non-epithelioid, consisting of 18 clinical specimens and five established cell lines. In examining these samples for homozygous deletions and sequence-level mutations, we found biallelic BAP1 gene alterations in 14 of 23 MMs (61%). Seven of these 14 MMs had homozygous deletions of the partial or entire BAP1 gene, another five had sequence-level mutations, including small deletions, a nonsense mutation, and missense mutations with additional monoallelic deletions, and the remaining two had homozygous mutations without allelic loss. All but one of the 14 BAP1 gene mutations were found in the epithelioid-type MMs; BAP1 mutations were found in 13 of 16 epithelioid-type MMs, but in only one of seven non-epithelioid-type MMs (13/16 vs 1/7; P = 0.005). There was no BAP1 mRNA expression in MMs with biallelic deletion and repressed expression was confirmed in MM specimens with deletion/mutation as compared with Met5a, SV40-transformed normal mesothelial cells. Western blot showed that seven of eight epithelioid MMs analyzed were BAP1 negative. Immunostaining with anti-BAP1 antibody in normal lung tissues revealed clear nuclear staining of normal mesothelial cells. No nuclear staining was observed among BAP1 mutation-positive MM tumors, whereas nuclear staining was observed among BAP1 mutation-negative MM tumors. These results suggest that the lack of the tumor suppressor BAP1 may be more specifically involved in the pathogenesis of epithelioid MM rather than non-epithelioid MM, and would be useful for diagnosis of epithelioid-type MM.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321046     DOI: 10.1111/j.1349-7006.2012.02223.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  59 in total

Review 1.  BAP1, a tumor suppressor gene driving malignant mesothelioma.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer.

Authors:  Moubin Lin; Liren Zhang; Michelle A T Hildebrandt; Maosheng Huang; Xifeng Wu; Yuanqing Ye
Journal:  Oncotarget       Date:  2017-08-24

3.  Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Authors:  Marjorie G Zauderer; Matthew Bott; Robert McMillan; Camelia S Sima; Valerie Rusch; Lee M Krug; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

4.  Recent insights emerging from malignant mesothelioma genome sequencing.

Authors:  Michele Carbone; Giovanni Gaudino; Haining Yang
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

5.  Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Authors:  Jinfei Xu; Yuwaraj Kadariya; Mitchell Cheung; Jianming Pei; Jacqueline Talarchek; Eleonora Sementino; Yinfei Tan; Craig W Menges; Kathy Q Cai; Samuel Litwin; Hongzhuang Peng; Jayashree Karar; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2014-06-13       Impact factor: 12.701

Review 6.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

7.  Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Authors:  Aaron S Mansfield; Tobias Peikert; James B Smadbeck; Julia B M Udell; Enrique Garcia-Rivera; Laura Elsbernd; Courtney L Erskine; Virginia P Van Keulen; Farhad Kosari; Stephen J Murphy; Hongzheng Ren; Vishnu V Serla; Janet L Schaefer Klein; Giannoula Karagouga; Faye R Harris; Carlos Sosa; Sarah H Johnson; Wendy Nevala; Svetomir N Markovic; Aaron O Bungum; Eric S Edell; Haidong Dong; John C Cheville; Marie Christine Aubry; Jin Jen; George Vasmatzis
Journal:  J Thorac Oncol       Date:  2018-10-10       Impact factor: 15.609

8.  New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Authors:  Marc Ladanyi; Marjorie G Zauderer; Lee M Krug; Tatsuo Ito; Robert McMillan; Matthew Bott; Filippo Giancotti
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

9.  PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Authors:  James Brugarolas
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

10.  BAP1 protein is a progression factor in malignant pleural mesothelioma.

Authors:  Lisa Arzt; Franz Quehenberger; Iris Halbwedl; Thomas Mairinger; Helmut H Popper
Journal:  Pathol Oncol Res       Date:  2013-08-22       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.